Revenue: As of FY2026 Q1, the actual value is USD 117.7 M, beating the estimate of USD 104.46 M.EPS: As of FY2026 Q1, the actual value is USD 0.05, beating the estimate of USD -0.02.EBIT: As of FY2026 Q1, the actual value is USD -711 K.<h3>Acquisition of Naveris, Inc.</h3>CareDx, Inc. entered into an Agreement and Plan of Merger with Naveris, Inc. on April 28, 2026, to acquire Naveris, Inc. . At the closing of the transaction, CareDx, Inc. will pay Naveris’ equityholders an aggregate of $160.0 million in cash, subject to customary adjustments . Naveris’ equityholders are eligible to receive up to $100.0 million in additional cash consideration contingent upon the achievement of specified revenue-based milestones for fiscal years ending December 31, 2026, and December 31, 2027 . A portion of the closing consideration, equal to $5.0 million, will be deposited into an escrow account . The Securityholder Representative Reserve Fund Amount is $500,000.00 in cash, withheld from the Estimated Merger Consideration at Closing and paid to the Securityholder Representative . Transaction Expenses, including third-party fees, costs, and expenses related to the transaction, are the responsibility of the Parent at Closing . Milestone Payments are capped at $100,000,000.00 in aggregate and are based on detailed FY2026 and FY2027 revenue tiers .<h4>Naveris Financial Performance (Unaudited)</h4>Naveris reported unaudited revenue of $34 million in 2025 . For the first quarter of 2026, Naveris reported unaudited revenue of approximately $12 million . Gross margins for Naveris in the first quarter of 2026 were 65% . Naveris reported a net operating loss of - $0.2 million for the first quarter of 2026 . More than 130,000 commercial NavDx® tests have been performed to-date . Naveris employs approximately 100 individuals .<h3>Stock Repurchase Program</h3>On April 24, 2026, CareDx, Inc.’s Board of Directors authorized a new common stock repurchase program of up to $100 million in shares, valid for up to 24 months from April 30, 2026 . This new program is distinct from a previous $50 million stock repurchase program authorized in May 2025 . Repurchases under the new program will be funded from the company’s existing cash and cash equivalents or future cash flow .<h3>First Quarter 2026 Financial Highlights</h3><h4>Total Revenue</h4>CareDx, Inc. reported total revenue of $118 million for the first quarter ended March 31, 2026, marking a 39% increase year-over-year .<h4>Segment Revenue</h4><ul><li>Testing services revenue reached $91 million, an increase of 48% year-over-year . Testing services volume was approximately 54,900, up 17% year-over-year .</li><li>Patient and digital solutions revenue was $16 million, showing a 33% year-over-year growth .</li><li>Lab product revenue was $10 million, experiencing a 4% decline year-over-year .</li></ul><h4>Operational Metrics</h4><ul><li>GAAP net income was $3 million for Q1 2026, compared to a GAAP net loss of - $10 million for Q1 2025 .</li><li>Adjusted EBITDA was $19 million for Q1 2026, an increase from $5 million for Q1 2025 .</li><li>Average revenue per test was approximately $1,660, which included approximately $14 million in prior period revenue .</li><li>GAAP income from operations was $1,198 thousand for Q1 2026, compared to a loss of - $13,374 thousand for Q1 2025 .</li><li>GAAP gross profit for Q1 2026 was $84,071 thousand, with a GAAP gross margin of 71% . This compares to a GAAP gross profit of $56,270 thousand and a GAAP gross margin of 66% for Q1 2025 .</li><li>GAAP operating expenses included research and development of $21,416 thousand, sales and marketing of $30,373 thousand, and general and administrative expenses of $30,484 thousand for Q1 2026 . Litigation settlement expense was $600 thousand for Q1 2026, down from $5,360 thousand in Q1 2025 .</li></ul><h4>Cash Flow</h4><ul><li>Cash flow from operations was $4 million for Q1 2026 .</li><li>Net cash provided by operating activities (GAAP) was $4,333 thousand for Q1 2026, significantly up from - $26,584 thousand for Q1 2025 .</li><li>Capital expenditures (GAAP) were - $3,819 thousand for Q1 2026, compared to - $1,630 thousand for Q1 2025 .</li><li>Non-GAAP free cash flow was $514 thousand for Q1 2026, compared to - $28,214 thousand for Q1 2025 .</li></ul><h4>Unique Metrics / Business Developments</h4>CareDx, Inc. announced a definitive agreement to divest its Lab Products business for $170 million in cash consideration . The company launched VANTx™, an AI-powered clinical data and analytics platform .<h3>Outlook / Guidance</h3>For the full year 2026, CareDx, Inc. raised its revenue guidance to a range of $447 million to $465 million, up from the previously disclosed range of $420 million to $444 million . The company also raised its full year 2026 adjusted EBITDA guidance to be in the range of $43 million to $57 million . CareDx, Inc. will have sole discretion over the business operations of the acquired entity, Naveris, Inc., and provides no assurance that any Milestone Event for the contingent payments will be achieved as they are considered speculative . Naveris’s 2025 revenue of $34 million is expected to grow 30-40% annually for the next three years, and the acquisition is estimated to be neutral to CareDx, Inc.’s FY2026 Adjusted EBITDA guidance . The transaction is anticipated to close in the third quarter of 2026 .

Caredex | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 117.7 M